Page last updated: 2024-08-23

elliptinium and Bone Marrow Diseases

elliptinium has been researched along with Bone Marrow Diseases in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abele, R; Brugarolas, A; Cavalli, F; Clarysse, A; de Jager, R; Hansen, HH; Renard, G; Rozencweig, M; Siegenthaler, P1
Crespeigne, N; Cumps, E; Dodion, P; Kenis, Y; Kisner, D; Nicaise, C; Piccart, M; Rozencweig, M1

Other Studies

2 other study(ies) available for elliptinium and Bone Marrow Diseases

ArticleYear
Phase II study of 9-hydroxy-2N-methylellipticinium acetate.
    European journal of cancer & clinical oncology, 1984, Volume: 20, Issue:2

    Topics: Adult; Aged; Alkaloids; Antineoplastic Agents; Bone Marrow Diseases; Breast Neoplasms; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Evaluation; Ellipticines; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms

1984
Phase I clinical study of 9-hydroxy-2N-methyl-ellipticinium acetate (NSC-264137) administered on a 5-day i.v. schedule.
    European journal of cancer & clinical oncology, 1982, Volume: 18, Issue:6

    Topics: Adult; Aged; Alkaloids; Antineoplastic Agents; Bone Marrow Diseases; Drug Administration Schedule; Drug Evaluation; Ellipticines; Female; Humans; Male; Middle Aged; Neoplasms

1982